A true tumor microenvironment is composed of many different cell types within an organ, including tumor cells, stromal cells, immune cells, pericytes, endothelial cells, and the extracellular matrix (ECM). Culturing these cells in 3D allows them to acquire tissue-like characteristics. Although only tens of micrometers in size, these 3D structures retain the complexity of tissues, creating an environment that closely mimics the in vivo situation.

CellBall Biomedical establishes 3D cell-based drug screening models using next-generation tumor cell lines within an ECM-mimicking environment. This provides researchers with conditions that closely resemble the true tumor microenvironment, yielding more accurate and reliable drug screening results, saving valuable time, and accelerating the progress of experimental development.

New drugs may cause toxicity or damage to various organs and tissues, and such toxic effects can be detected early using corresponding 2D cell-based drug screening models. Before clinical trials or market approval, new drugs must undergo a series of preclinical toxicity assessments to provide safety information.

CellBall Biomedical’s professional team, leveraging years of expertise, customizes drug screening programs according to clients’ research needs and objectives. This includes the design of screening criteria, reagent selection, and experimental planning, as well as professional data analysis to interpret results in detail and generate comprehensive reports, supporting further research and drug efficacy evaluation.